Immune checkpoint inhibitors in cancer therapy: what lies beyond monoclonal antibodies?
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61388963%3A_____%2F25%3A00636902" target="_blank" >RIV/61388963:_____/25:00636902 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11310/25:10515644
Result on the web
<a href="https://doi.org/10.1007/s12032-025-02822-1" target="_blank" >https://doi.org/10.1007/s12032-025-02822-1</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1007/s12032-025-02822-1" target="_blank" >10.1007/s12032-025-02822-1</a>
Alternative languages
Result language
angličtina
Original language name
Immune checkpoint inhibitors in cancer therapy: what lies beyond monoclonal antibodies?
Original language description
Immune checkpoints are critical in modulating immune responses and maintaining self-tolerance. Cancer cells can exploit these mechanisms to evade immune detection, making immune checkpoints attractive targets for cancer therapy. The introduction of immune checkpoint inhibitors (ICIs) has transformed cancer treatment, with monoclonal antibodies targeting CTLA-4, PD-1, and PD-L1 demonstrating clinical success. However, challenges such as immune-related adverse events, primary and acquired resistance, and high treatment costs persist. To address these challenges, it is essential to explore alternative strategies, including small-molecule and peptide-based inhibitors, aptamers, RNA-based therapies, gene-editing technologies, bispecific and multispecific agents, and cell-based therapies. Additionally, innovative approaches such as lysosome-targeting chimeras, proteolysis-targeting chimeras, and N-(2-hydroxypropyl) methacrylamide copolymers are emerging as promising options for enhancing treatment effectiveness. This review highlights significant advancements in the field, focusing on their clinical implications and successes.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30107 - Medicinal chemistry
Result continuities
Project
Result was created during the realization of more than one project. More information in the Projects tab.
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2025
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Medical Oncology
ISSN
1357-0560
e-ISSN
1559-131X
Volume of the periodical
42
Issue of the periodical within the volume
7
Country of publishing house
US - UNITED STATES
Number of pages
14
Pages from-to
273
UT code for WoS article
001512016400004
EID of the result in the Scopus database
2-s2.0-105008740839